Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NPD's Cash to Debt is ranked higher than
96% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.47 vs. NPD: No Debt )
NPD' s 10-Year Cash to Debt Range
Min: 27.67   Max: No Debt
Current: No Debt

Equity to Asset 0.56
NPD's Equity to Asset is ranked higher than
85% of the 523 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NPD: 0.56 )
NPD' s 10-Year Equity to Asset Range
Min: 0   Max: 0.87
Current: 0.56

0
0.87
Interest Coverage No Debt
NPD's Interest Coverage is ranked higher than
99% of the 381 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.78 vs. NPD: No Debt )
NPD' s 10-Year Interest Coverage Range
Min: 17.73   Max: 9999.99
Current: No Debt

17.73
9999.99
F-Score: 4
Z-Score: 3.64
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.96
NPD's Operating margin (%) is ranked higher than
50% of the 524 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.53 vs. NPD: -0.96 )
NPD' s 10-Year Operating margin (%) Range
Min: -2.92   Max: 9.25
Current: -0.96

-2.92
9.25
Net-margin (%) -0.89
NPD's Net-margin (%) is ranked higher than
51% of the 524 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. NPD: -0.89 )
NPD' s 10-Year Net-margin (%) Range
Min: -2.75   Max: 8.04
Current: -0.89

-2.75
8.04
ROE (%) -2.74
NPD's ROE (%) is ranked higher than
51% of the 514 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.04 vs. NPD: -2.74 )
NPD' s 10-Year ROE (%) Range
Min: -5174.35   Max: 10.04
Current: -2.74

-5174.35
10.04
ROA (%) -1.55
NPD's ROA (%) is ranked higher than
51% of the 524 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.13 vs. NPD: -1.55 )
NPD' s 10-Year ROA (%) Range
Min: -19.18   Max: 7.32
Current: -1.55

-19.18
7.32
ROC (Joel Greenblatt) (%) -7.63
NPD's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 523 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.29 vs. NPD: -7.63 )
NPD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20.69   Max: 115.93
Current: -7.63

-20.69
115.93
Revenue Growth (%) 10.00
NPD's Revenue Growth (%) is ranked higher than
89% of the 462 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. NPD: 10.00 )
NPD' s 10-Year Revenue Growth (%) Range
Min: -11.5   Max: 58.9
Current: 10

-11.5
58.9
EBITDA Growth (%) -16.20
NPD's EBITDA Growth (%) is ranked higher than
55% of the 423 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NPD: -16.20 )
NPD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 122.4
Current: -16.2

0
122.4
EPS Growth (%) -6.50
NPD's EPS Growth (%) is ranked higher than
66% of the 403 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.00 vs. NPD: -6.50 )
NPD' s 10-Year EPS Growth (%) Range
Min: -52.1   Max: -6.5
Current: -6.5

-52.1
-6.5
» NPD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NPD Guru Trades in Q3 2013

Jim Simons 428,900 sh (+3.05%)
» More
Q4 2013

NPD Guru Trades in Q4 2013

Jim Simons 463,700 sh (+8.11%)
» More
Q1 2014

NPD Guru Trades in Q1 2014

Jim Simons 634,771 sh (+36.89%)
» More
Q2 2014

NPD Guru Trades in Q2 2014

Jim Simons 560,600 sh (-11.68%)
» More
» Details

Insider Trades

Latest Guru Trades with NPD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.34
NPD's P/B is ranked higher than
77% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. NPD: 1.34 )
NPD' s 10-Year P/B Range
Min: 0.69   Max: 4.77
Current: 1.34

0.69
4.77
P/S 0.39
NPD's P/S is ranked higher than
73% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. NPD: 0.39 )
NPD' s 10-Year P/S Range
Min: 0.36   Max: 6.68
Current: 0.39

0.36
6.68
Shiller P/E 23.01
NPD's Shiller P/E is ranked higher than
83% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 31.09 vs. NPD: 23.01 )
NPD' s 10-Year Shiller P/E Range
Min: 10.13   Max: 43.5
Current: 23.01

10.13
43.5
Current Ratio 2.02
NPD's Current Ratio is ranked higher than
91% of the 524 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.17 vs. NPD: 2.02 )
NPD' s 10-Year Current Ratio Range
Min: 1.17   Max: 6.94
Current: 2.02

1.17
6.94
Quick Ratio 1.05
NPD's Quick Ratio is ranked higher than
85% of the 524 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.68 vs. NPD: 1.05 )
NPD' s 10-Year Quick Ratio Range
Min: 0.49   Max: 6.33
Current: 1.05

0.49
6.33

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 17.10
NPD's Dividend Yield is ranked higher than
99% of the 450 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.87 vs. NPD: 17.10 )
NPD' s 10-Year Dividend Yield Range
Min: 0.86   Max: 16.15
Current: 17.1

0.86
16.15
Dividend growth (3y) 3.70
NPD's Dividend growth (3y) is ranked higher than
76% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. NPD: 3.70 )
NPD' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 3.7
Current: 3.7

0
3.7
Yield on cost (5-Year) 17.10
NPD's Yield on cost (5-Year) is ranked higher than
98% of the 455 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. NPD: 17.10 )
NPD' s 10-Year Yield on cost (5-Year) Range
Min: 0.86   Max: 16.15
Current: 17.1

0.86
16.15
Share Buyback Rate 2.10
NPD's Share Buyback Rate is ranked higher than
90% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. NPD: 2.10 )
NPD' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -27.1
Current: 2.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.43
NPD's Price/Tangible Book is ranked higher than
81% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.40 vs. NPD: 1.43 )
NPD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 4.59
Current: 1.43

0.96
4.59
Price/DCF (Projected) 1.04
NPD's Price/DCF (Projected) is ranked higher than
90% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.17 vs. NPD: 1.04 )
NPD' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 42.56
Current: 1.04

0.8
42.56
Price/Median PS Value 0.34
NPD's Price/Median PS Value is ranked higher than
99% of the 537 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.09 vs. NPD: 0.34 )
NPD' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 5.58
Current: 0.34

0.32
5.58
Forward Rate of Return (Yacktman) -30.74
NPD's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 430 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.22 vs. NPD: -30.74 )
NPD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.9   Max: -0.5
Current: -30.74

-27.9
-0.5

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:WAG, RAD, PETS, DSCM, CVS, PERF » details
Traded in other countries:4CSA.Germany
China Nepstar Chain Drugstore Ltd. is incorporated in the Cayman Islands on August 20, 2004. Since its inception, the Company has conducted its operations in China mainly through Nepstar Pharmaceutical, which became a wholly foreign-owned enterprise in China in August 2004 as the result of its restructuring in 2004. The Company and its subsidiaries are mainly engaged in the business of operating retail drugstores in the People's Republic of China (PRC). It provides its customers with quality, professional and convenient pharmacy services and a variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. It offers various types of drinkable herbal remedies and packages of assorted herbs for making soup, which are used by consumers as health supplements. its other products include personal care products such as skin care, hair care and beauty products, family care products such as portable medical devices for family use, birth control and early pregnancy test products and convenience products, including soft drinks, packaged snacks, and other consumables, cleaning agents and stationery. Its merchandise could be classified into the following categories: Prescription Drugs, OTC Drugs, Nutritional Supplements, Herbal Products and Other Products. The Company currently sources its merchandise from regional manufacturers and wholesalers. Its typical customers are urban residents in major Chinese cities. Its sales to retail customers are paid by cash or debit or credit cards, or by medical insurance cards under the national medical insurance program. The drugstore industry in China is intensely competitive, rapidly evolving and fragmented. The Company mainly competes with other retail drugstore chains or independent drugstores. As a distributor and retailer of pharmaceutical products, the Company is subject to regulation and oversight by different levels of the food and drug administration in China, in particular, the SFDA.
» More Articles for NYSE:NPD

Headlines

Articles On GuruFocus.com
High Yield George Soros Stocks: China Nepstar ADS, Chimera Investment, PDL BioPharma, MFA Mortgage I Apr 22 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results Aug 24 2009 
China Nepstar Chain Drugstore Announces Special Dividend Aug 24 2009 
Ron Baron Likes Layne Christensen, Ritchie Brothers Auctioneers, Bankrate and China Nepstar Mar 25 2008 

More From Other Websites
Baiyunshan's "Golden Spear" Targets Sweet Spot with Viagra Clone Oct 16 2014
What Falling Estimates & Price Mean for China Nepstar Chain Drugstore (NPD) Oct 13 2014
China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 Sep 22 2014
China Nepstar Chain Drugstore Ltd. Earnings Call scheduled for 8:00 am ET today Aug 28 2014
China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results Aug 28 2014
China Nepstar Chain Drugstore to Report Second Quarter 2014 Financial Results on August 28, 2014 Aug 05 2014
China Nepstar Chain Drugstore Announces Change of Director Jun 13 2014
China Nepstar reports Q1 EPS (3c), one estimate 0c May 29 2014
China Nepstar Chain Drugstore Ltd. Reports First Quarter 2014 Financial Results May 29 2014
China Nepstar Chain Drugstore to Report First Quarter 2014 Financial Results on May 29, 2014 May 09 2014
CHINA NEPSTAR CHAIN DRUGSTORE LTD. Financials Apr 26 2014
China Nepstar Chain Drugstore Filed 2013 Annual Report on Form 20-F Apr 22 2014
Rite Aid Gains on Health Dialog Buyout Apr 02 2014
China Nepstar's CEO Discusses Q4 2013 Results - Earnings Call Transcript Mar 28 2014
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2013 Financial Results Mar 28 2014
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2013 Financial Results Mar 28 2014
China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2013 Financial Results on... Mar 07 2014
China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2013 Financial Results on... Mar 07 2014
What To Hold: 5 Hold-Rated Dividend Stocks NPD, MCEP, EFC, DX, PDH Jan 06 2014
What To Hold: 5 Hold-Rated Dividend Stocks NPD, BKCC, BGCP, HRZN, MCEP Dec 19 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK